These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21487418)

  • 21. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
    Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
    J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating the risks and benefits of tamoxifen for prophylactic breast cancer chemoprevention in Korea.
    Kim DU; Min JW; Kim YM; Chang MC
    J Breast Cancer; 2012 Mar; 15(1):51-6. PubMed ID: 22493628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview from the International Conference on Long-Term Tamoxifen Therapy for Breast Cancer.
    Jordan VC
    J Natl Cancer Inst; 1992 Feb; 84(4):231-4. PubMed ID: 1346404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention.
    Curtis MG
    Drug Saf; 2001; 24(14):1039-53. PubMed ID: 11735660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
    Powles TJ; Ashley S; Tidy A; Smith IE; Dowsett M
    J Natl Cancer Inst; 2007 Feb; 99(4):283-90. PubMed ID: 17312305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    Levine M; Moutquin JM; Walton R; Feightner J;
    CMAJ; 2001 Jun; 164(12):1681-90. PubMed ID: 11450210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tamoxifen inhibits lipid peroxidation in cardiac microsomes. Comparison with liver microsomes and potential relevance to the cardiovascular benefits associated with cancer prevention and treatment by tamoxifen.
    Wiseman H; Cannon M; Arnstein HR; Halliwell B
    Biochem Pharmacol; 1993 May; 45(9):1851-5. PubMed ID: 8494544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
    Fagerlin A; Dillard AJ; Smith DM; Zikmund-Fisher BJ; Pitsch R; McClure JB; Greene S; Alford SH; Nair V; Hayes DF; Wiese C; Ubel PA
    Breast Cancer Res Treat; 2011 Jun; 127(3):681-8. PubMed ID: 21442198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: an analysis of the tradeoffs.
    Nease RF; Ross JM
    Am J Med; 1995 Aug; 99(2):180-9. PubMed ID: 7625423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential role of tamoxifen in prevention of breast cancer.
    Nayfield SG; Karp JE; Ford LG; Dorr FA; Kramer BS
    J Natl Cancer Inst; 1991 Oct; 83(20):1450-9. PubMed ID: 1920492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term consequences of ovarian ablation for premenopausal breast cancer.
    Kwon JS; Pansegrau G; Nourmoussavi M; Hammond G; Carey MS
    Breast Cancer Res Treat; 2016 Jun; 157(3):565-73. PubMed ID: 27236562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term tamoxifen therapy to control or to prevent breast cancer: laboratory concept to clinical trials.
    Jordan VC
    Prog Clin Biol Res; 1988; 262():105-23. PubMed ID: 3287387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer.
    Rutqvist LE; Johansson H;
    Acta Oncol; 2007; 46(2):133-45. PubMed ID: 17453361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer.
    Jordan VC
    Annu Rev Pharmacol Toxicol; 1995; 35():195-211. PubMed ID: 7598491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescription of tamoxifen for breast cancer prevention by primary care physicians.
    Armstrong K; Quistberg DA; Micco E; Domchek S; Guerra C
    Arch Intern Med; 2006 Nov; 166(20):2260-5. PubMed ID: 17101945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk-benefit profiles of women using tamoxifen for chemoprevention.
    Nichols HB; DeRoo LA; Scharf DR; Sandler DP
    J Natl Cancer Inst; 2015 Jan; 107(1):354. PubMed ID: 25475563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.
    Grann VR; Jacobson JS; Thomason D; Hershman D; Heitjan DF; Neugut AI
    J Clin Oncol; 2002 May; 20(10):2520-9. PubMed ID: 12011131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer.
    Kwon JS; Pansegrau G; Nourmoussavi M; Hammond GL; Carey MS
    J Natl Compr Canc Netw; 2017 Aug; 15(8):1015-1021. PubMed ID: 28784863
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.